Search Results - "Miyawaki, Taichi"

Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer by Miyawaki, Taichi, Naito, Tateaki, Yabe, Michitoshi, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Takahashi, Kazuhisa, Takahashi, Toshiaki

“…Purpose Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors plus chemotherapy have become the standard first line of treatment in…”
Get full text

Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma by Kodama, Hiroaki, Wakuda, Kazushige, Yabe, Michitoshi, Nishioka, Naoya, Miyawaki, Eriko, Miyawaki, Taichi, Mamesaya, Nobuaki, Kawamura, Takahisa, Kobayashi, Haruki, Omori, Shota, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Endo, Masahiro, Takahashi, Toshiaki

“…Summary Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has exhibited efficacy in patients with…”
Get full text

Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study by Kurokawa, Kana, Mitsuishi, Yoichiro, Shimada, Naoko, Kawakami, Yuta, Miura, Keita, Miyawaki, Taichi, Asao, Tetsuhiko, Ko, Ryo, Shukuya, Takehito, Shibayama, Rina, Nojiri, Shuko, Takahashi, Kazuhisa

“…Abstract Background The combination of immune-checkpoint inhibitors with chemotherapy has become the standard of treatment for non-small cell lung cancer…”
Get full text

Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma by Iida, Yuko, Wakuda, Kazushige, Kenmotsu, Hirotsugu, Doshita, Kosei, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Miyawaki, Taichi, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Sugino, Takashi, Gon, Yasuhiro, Takahashi, Toshiaki

“…The efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) is unclear. This study aimed to evaluate the…”
Get full text

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer by Nishimura, Ari, Ono, Akira, Wakuda, Kazushige, Kawabata, Takanori, Yabe, Michitoshi, Miyawaki, Taichi, Miyawaki, Eriko, Kodama, Hiroaki, Nishioka, Naoya, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Harada, Hideyuki, Takahashi, Toshiaki

“…Summary Background.  Prognostic data on Japanese patients receiving durvalumab after chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer…”
Get full text

Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy by Noda‐Narita, Shoko, Naito, Tomoyuki, Udagawa, Hibiki, Goto, Koichi, Miyawaki, Taichi, Mamesaya, Nobuaki, Nakashima, Kazuhisa, Kenmotsu, Hirotsugu, Shimokawaji, Tadasuke, Kato, Terufumi, Hakozaki, Taiki, Okuma, Yusuke, Nakamura, Masaki, Nakayama, Yuko, Watanabe, Hirokazu, Kusumoto, Masahiko, Ohe, Yuichiro, Horinouchi, Hidehito

“…The role of previous thoracic radiation therapy as a risk factor of immune‐related pneumonitis is unclear. Furthermore, some patients develop radiation recall…”
Get full text

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer by Masuda, Takeshi, Miura, Satoru, Sato, Yuki, Tachihara, Motoko, Bessho, Akihiro, Nakamura, Atsushi, Miyawaki, Taichi, Yoshimine, Kohei, Mori, Masahide, Shiraishi, Hideaki, Hamai, Kosuke, Haratani, Koji, Maeda, Sumiko, Tabata, Eriko, Kitagawa, Chiyoe, Tanizaki, Junko, Imai, Takumi, Nogami, Shohei, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko, Hattori, Noboru

“…Small amounts of epidermal growth factor receptor ( EGFR ) T790M mutation (micro-T790M), which is detected using droplet digital PCR (ddPCR) but not…”
Get full text

Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy by Miyawaki, Taichi, Wakuda, Kazushige, Kenmotsu, Hirotsugu, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Notsu, Akifumi, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Ohde, Yasuhisa, Takahashi, Kazuhisa, Takahashi, Toshiaki

“…Despite the importance of accurate disease definitions for effective management and treatment decisions, there is currently no consensus on what constitutes…”
Get full text

Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L) by Miyawaki, Taichi, Kenmotsu, Hirotsugu, Harada, Hideyuki, Ohde, Yasuhisa, Chiba, Yasutaka, Haratani, Koji, Okimoto, Tamio, Sakamoto, Tomohiro, Wakuda, Kazushige, Ito, Kentaro, Uemura, Takehiro, Sakata, Shinya, Kogure, Yoshihito, Nishimura, Yasumasa, Nakagawa, Kazuhiko, Yamamoto, Nobuyuki

“…Synchronous oligometastatic non-small cell lung cancer (NSCLC) is generally characterised by the limited number of metastases at the time of diagnosis. Several…”
Get full text

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study by Miyawaki, Taichi, Kenmotsu, Hirotsugu, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Takahashi, Kazuhisa, Takahashi, Toshiaki

“…Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with…”
Get full text

Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis by Doshita, Kosei, Kenmotsu, Hirotsugu, Omori, Shota, Tabuchi, Yuya, Kawabata, Takanori, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Iida, Yuko, Miyawaki, Taichi, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Kaneko, Takeshi, Takahashi, Toshiaki

“…Summary Introduction : In patients with limited disease small cell lung cancer (LD-SCLC) treated with concurrent chemoradiotherapy (CCRT), long-term survival…”
Get full text

Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non–Small-Cell Lung Cancer by Miyawaki, Taichi, Kenmotsu, Hirotsugu, Mori, Keita, Miyawaki, Eriko, Mamesaya, Nobuaki, Kawamura, Takahisa, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Harada, Hideyuki, Endo, Masahiro, Ohde, Yasuhisa, Takahashi, Kazuhisa, Takahashi, Toshiaki

“…Programmed cell death 1 (PD-1) inhibitors have become a standard treatment, albeit not completely effective, for patients with advanced non–small-cell lung…”
Get full text

Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer by Nishimura, Ari, Ono, Akira, Wakuda, Kazushige, Kawabata, Takanori, Yabe, Michitoshi, Miyawaki, Taichi, Miyawaki, Eriko, Kodama, Hiroaki, Nishioka, Naoya, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Harada, Hideyuki, Takahashi, Toshiaki

Get full text

Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors by Wakuda, Kazushige, Yabe, Michitoshi, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Taichi, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Shimizu, Tetsuo, Gon, Yasuhiro, Takahashi, Toshiaki

“…Immune checkpoint inhibitors (ICIs) combined with chemotherapy have been approved as first-line treatment for patients with untreated extensive disease-small…”
Get full text

Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy by Mamesaya, Nobuaki, Muramatsu, Koji, Yabe, Michitoshi, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Taichi, Miyawaki, Eriko, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Harada, Hideyuki, Sugino, Takashi, Shimizu, Tetsuo, Gon, Yasuhiro, Takahashi, Toshiaki

“…Background The expression of programmed cell death-ligand 1 (PD-L1) is a biomarker for administering immune check point inhibitors in patients with advanced…”
Get full text

Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis by Miyawaki, Taichi, Kenmotsu, Hirotsugu, Yabe, Michitoshi, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Deguchi, Shoichi, Mitsuya, Koichi, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Hayashi, Nakamasa, Takahashi, Kazuhisa, Takahashi, Toshiaki

“…Summary Objectives In EGFR -mutated non-small cell lung cancer (NSCLC) patients, approximately 80–90% of leptomeningeal metastasis (LM) develops after failed…”
Get full text

Second malignancy in advanced or recurrent non‐small cell lung cancer after the advent of molecular targeted drugs and immunotherapy by Masui, Yoshihiro, Shukuya, Takehito, Kataoka, Shunichi, Shiozaki, Hitomi, Kurokawa, Kana, Nakamura, Ikuko, Miyawaki, Taichi, Koinuma, Yoshika, Asao, Tetsuhiko, Kanemaru, Ryota, Shimamura, Shoko Sonobe, Mimori, Tomoyasu, Mitsuishi, Yoichiro, Tajima, Ken, Shimada, Naoko, Takahashi, Kazuhisa

“…Objectives This study aimed to investigate the characteristics of patients with recurrent or advanced non‐small cell lung cancer (NSCLC) treated with tyrosine…”
Get full text

Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines by Xu, Shiting, Miura, Keita, Shukuya, Takehito, Harada, Sonoko, Fujioka, Masahiro, Winardi, Wira, Shimamura, Shoko, Kurokawa, Kana, Sumiyoshi, Issei, Miyawaki, Taichi, Asao, Tetsuhiko, Mitsuishi, Yoichiro, Tajima, Ken, Takahashi, Fumiyuki, Hayashi, Takuo, Harada, Norihiro, Takahashi, Kazuhisa

“…Cancer cachexia is associated with poor immunotherapeutic outcomes. This prospective observational study longitudinally evaluated the role of cachexia-related…”
Get full text

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis by Xu, Shiting, Shukuya, Takehito, Tamura, Jun, Shimamura, Shoko, Kurokawa, Kana, Miura, Keita, Miyawaki, Taichi, Hayakawa, Daisuke, Asao, Tetsuhiko, Yamamoto, Kouji, Takahashi, Kazuhisa

“…Outcomes of immune checkpoint inhibitor (ICI) rechallenge in NSCLC remain uncertain. This study estimated the safety and efficacy of ICI rechallenge and…”
Get full text

Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer by Nishioka, Naoya, Naito, Tateaki, Miyawaki, Taichi, Yabe, Michitoshi, Doshita, Kosei, Kodama, Hiroaki, Miyawaki, Eriko, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Takayama, Koichi, Takahashi, Toshiaki

“…Background Adipose tissue induces inflammation, which desensitizes the efficacy of immunotherapy. However, several reports show that the therapeutic effect of…”
Get full text